Key result
Naringenin significantly attenuated left ventricular hypertrophy and decreased angiotensin II and ACE1 protein levels in myocardial tissues in rats with L-NAME-induced hypertension.
Why the study?
Does naringenin prevent left ventricular hypertrophy in a rat model of L-NAME-induced hypertension?
Does naringenin prevent left ventricular hypertrophy in a rat model of L-NAME-induced hypertension?
Naringenin attenuates pressure overload-induced left ventricular hypertrophy in rats by downregulating ACE1 and Ang II expression in cardiac tissue.
Answers are grounded in this paper and cite their sources.
Naringenin effects on LVH should not change practice; hypothesis-generating for ACE1/Ang II modulation in hypertensive remodeling models.
-nitro-L-arginine methyl ester (L-NAME)-induced hypertension, and sought to determine the underlying mechanism of action. The rats received the following by gavage daily for 56 days: L-NAME (50 mg/kg/day) + NGN (100 mg/kg/day), L-NAME (50 mg/kg/day) + saline, or saline + saline. Blood pressure, heart rate and body weight were recorded. Left ventricular hypertrophy was assessed by echocardiography and hematoxylin-eosin staining. Angiotensin II (Ang II) and angiotensin-converting enzyme 1 (ACE1), which serve a pivotal role in cardiac remodeling, were evaluated by ELISA, reverse transcription-quantitative polymerase chain reaction and western blot analysis. NGN had no significant effect on body weight, heart rate or blood pressure. The extent of left ventricular hypertrophy in the L-NAME + NGN group was lower than in the L-NAME + saline group on day 56. NGN decreased Ang II and ACE1 protein levels in myocardial tissues. In conclusion, Ang II and ACE1 expression in cardiac tissue was inhibited by NGN in L-NAME-treated rats, which may contribute to the inhibitory effects of NGN on left ventricular hypertrophy that is induced by pressure overload.
No takes yet. Share an insight, caveat, or question.
Gao et al. (2018) studied Left ventricular hypertrophy and hypertension (n=30). Naringenin vs. L-NAME + saline was evaluated on Left ventricular hypertrophy (interventricular septal thickness, left ventricular posterior wall thickness, cardiomyocyte cross-sectional area) (p=<0.05). Naringenin significantly attenuated left ventricular hypertrophy and decreased angiotensin II and ACE1 protein levels in myocardial tissues in rats with L-NAME-induced hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: